Condition
Mucopolysaccharidosis III-B
Total Trials
5
Recruiting
1
Active
1
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 60/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
50.0%
-36.6% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results50% success
Data Visualizations
Phase Distribution
3Total
P 1 (3)
Trial Status
Not Yet Recruiting1
Recruiting1
Completed1
Terminated1
Enrolling By Invitation1
Trial Success Rate
50.0%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT05368038Enrolling By Invitation
ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program
NCT07640984Phase 1Not Yet RecruitingPrimary
A Phase I/II Trial of JR-446 in Mucopolysaccharidosis Type IIIB (MPS IIIB)
NCT06488924Phase 1RecruitingPrimary
An Open-label Phase I/II Study of JR-446 in Mucopolysaccharidosis Type IIIB
NCT04655911TerminatedPrimary
A Long-term Follow-up Study of Patients With MPS IIIB Treated With ABO-101
NCT02324049Phase 1CompletedPrimary
Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB)
Showing all 5 trials